Assessment of adherence to routine vaccination schedules in oncology patients

Abstract

Introduction

Patients diagnosed with cancer are at an increased risk of infection. Vaccines remain one of the most critical public health strategies in limiting infectious diseases, with a heightened importance in cancer patients. Data across the general US population indicates that vaccine adherence rates are suboptimal across all adult vaccine schedules. This study aims to define vaccine adherence rates within the oncology population.

Methods

This retrospective cohort study includes adult patients with a new cancer diagnosis. Vaccine administrations for COVID-19 (SARS-CoV-2), influenza, pneumococcal, tetanus/diphtheria/pertussis (TDaP), herpes zoster (RZV), human papillomavirus (HPV), and hepatitis B (hepB) were assessed. The primary outcome was complete vaccine adherence.

Results

Two hundred and eighty-three oncology patients were included. The median age at diagnosis was 63 years old, and most subjects were females (60%). The two most common malignancies were gastrointestinal and breast cancer at 26.5% and 15.2%, respectively. Suboptimal vaccine adherence rates were observed across the entire oncology population. Complete adherence was observed in only 1.4% of patients. Vaccine specific adherence rates were as follows, SARS-CoV-2: 38.9%; influenza: 11.4%; pneumococcal: 12.7%; TDaP: 13.1%; RZV: 3.5%; HPV: 0%; and hepB: 34%. Among the vaccine schedules assessed, SARS-CoV-2 vaccination rates were the highest with 38.9% of patients being fully adherent and 73% receiving at least one dose.

Conclusion

Lower vaccine adherence rates were observed in oncology patients compared to currently published rates. Providers and pharmacists can play a role in assessing and counseling patients on the importance of vaccine adherence before chemotherapy is initiated and after a remission is obtained.

Keywords

Vaccines infectious disease oncology

Get full access to this article

View all access options for this article.

References

Palmore

Parta

Cuellar-Rodriguez

, et al. Infections in the cancer patient. In: DeVita

Lawrence

Rosenberg

(eds) Devita, Hellman, and Rosenberg’s cancer: principles and practice of oncology. 11th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2019, pp.2037–2068.

Rolston

. Infections in cancer patients with solid tumors: a review. Infect Dis Ther 2017; 6: 69–83.

Centers for disease control and prevention. Adult immunization schedule. Accessed July 23, 2022. Available at: https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html.

Hibberd

Rubin

. Approach to immunization in the immunosuppressed host. Infect Dis Clin North Am 1990; 4: 123–142.

Centers for disease control and prevention. Vaccine recommendations and guidelines for the ACIP. Accessed August 6, 2022. Available at: https://www.cdc.gov/vaccines/hcp/acip-recs/general recs/contraindications.html # ref-16.

McCullers

Dunn

. Advances in vaccine technology and their impact on managed care. P T 2008; 33: 35–41.

Taplitz

Kennedy

Bow

, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol 2018; 36: 3043–3054.

Kroger

Bahta

Hunter

. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html (accessed on July 23, 2022).

Rubin

Levin

Ljungman

, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58: e44–100.

10.

Salo

. Effects of anaesthesia and surgery on the immune response. Acta Anaesthesiol Scand 1992; 36: 201–220.

11.

Hung

Srivastav

, et al. Surveillance of vaccination coverage among adult populations—United States, 2018. MMWR Surveill Summ 2021; 70: 1–26.

12.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prevention and Treatment of Cancer-Related Infections Guideline Name V.1.2023. © National Comprehensive Cancer Network, Inc. 20XX. All rights reserved. Accessed [October 3, 2023]

13.

Ariza-Heredia

Chemaly

. Practical review of immunizations in adult patients with cancer. Hum Vaccin Immunother 2015; 11: 2606–2614.

14.

Cerio

Schad

Morley

. Relationship between COVID-19 cases and vaccination rates in New York State counties. Ann Fam Med 2022; 17: e0271625.

15.

Singh

Chase

. Measuring vaccine acceptance and knowledge within health professions education. Vaccine 2022; 40: 5452–5458.

16.

Butow

Shaw

Bartley

, et al. Vaccine hesitancy in cancer patients: a rapid review. Patient Educ Couns 2023; 111: 107680.

17.

Abdolkarimi

Amanati

Molavi Vardanjani

, et al. Antibody waning after immunosuppressive chemotherapy and immunomodulators, re-immunization considerations in pediatric patients with malignancy and chronic immune thrombocytopenic purpura. BMC Infect Dis 2022; 22: 657.